Johnson Matthey partners with Immunomedics to develop life-saving cancer treatment
09 January 2019
Johnson Matthey (LSE: JMAT), a global leader in science that enables a cleaner and healthier world, today announced a strategic manufacturing partnership for the large-scale production of the drug-linker used in Immunomedics’ lead antibody-drug conjugate.
The antibody-drug conjugate, sacituzumab govitecan, is a treatment for patients with metastatic triple-negative breast cancer, currently under priority review by the FDA for accelerated approval. If approved, sacituzumab govitecan would be the first therapy approved for this patient group.
The drug-linker CL2A-SN-38 is a critical component in the novel antibody-drug conjugate. This key constituent is being produced at JM’s Devens, MA facility. Immunomedics has significantly scaled the ongoing partnership due to JM’s track-record in high potency GMP manufacturing and proven chemical and analytical development for scale-up and production of complex molecules.
“We are proud to build on our existing relationship with Immunomedics to enable the production of viable treatment options to improve cancer patients’ lives,” said Nick Shackley, Vice President, Health. “This long-term master supply agreement signifies our continuing dedication to help companies deliver novel treatments and medicines, to create a healthier world.”